---
title: "\"MABPHARM\" achieved a net profit of 57.13 million RMB for the entire year, turning a loss into a profit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280650013.md"
description: "MABPHARM-B announced its performance for the fiscal year 2025, with operating revenue of 646 million RMB, an increase of 150.2% year-on-year. It recorded a net profit of 57.13 million RMB, compared to a loss of 128 million RMB in the previous year, turning from loss to profit; earnings per share are 0.01 RMB. No final dividend is declared"
datetime: "2026-03-26T14:27:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280650013.md)
  - [en](https://longbridge.com/en/news/280650013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280650013.md)
generator: "portal-rs"
---

# "MABPHARM" achieved a net profit of 57.13 million RMB for the entire year, turning a loss into a profit

MABPHARM-B (02181.HK) announced its 2025 annual performance, with operating revenue of 646 million RMB (same below), an increase of 150.2% year-on-year. It recorded a net profit of 57.13 million yuan, compared to a loss of 128 million yuan in the previous year, turning from loss to profit; earnings per share of 1 cent. No final dividend is declared

### Related Stocks

- [02181.HK](https://longbridge.com/en/quote/02181.HK.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal](https://longbridge.com/en/news/298111133.md)
- [With Its War On Prediction Markets, The Gaming Lobby Plays A Bad Hand](https://longbridge.com/en/news/298117381.md)
- [J&T Global Express grants 45,696,708 Class B share awards under 2024 incentive scheme](https://longbridge.com/en/news/298037641.md)
- [Sands China shifts to alternative HKEX public float rule after stake buy drops float below 25%](https://longbridge.com/en/news/297631055.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**